Table 1.
Clinical characteristics of the study population.
| Total (N=157,861) | BA.2 (n=34,336) | BA.5 (n=123,525) | |
|---|---|---|---|
| Median age (range)-yr | 33 (0-104) | 28 (0-102) | 34 (0-104) |
| Age * – no. (%) | |||
| < 10 | 23,219 (14·7) | 6,427 (18·8) | 16,792 (13·6) |
| 10s | 21,165 (13·4) | 6,012 (17·6) | 15,153 (12·3) |
| 20s | 26,259 (16·7) | 5,667 (16·6) | 20,592 (16·7) |
| 30s | 27,665 (17·6) | 6,093 (17·8) | 21,572 (17·5) |
| 40s | 26,536 (16·8) | 5,465 (16·) | 21,071 (17·1) |
| 50s | 16,629 (10·6) | 2,434 (7·1) | 14,195 (11·5) |
| 60s | 8,881 (5·6) | 1,156 (3·4) | 7,725 (6·3) |
| 70s | 4,839 (3·1) | 647 (1·9) | 4,192 (3·4) |
| ≥ 80 | 2,359 (1·5) | 310 (0·9) | 2,049 (1·7) |
| Elderly (Age ≥ 65) – no. (%) | 10,874 (9·3) | 1,441 (9·6) | 9,433 (7·6) |
| Sex ** – no. (%) | |||
| Male | 75,281 (47·7) | 16,292 (47·5) | 58,989 (47·8) |
| Female | 82,468 (52·3) | 18,012 (52·5) | 64,456 (52·2) |
| Median BMI *** (IQR) | 21·1 (18·6-24·0) | 20·7 (18·1-23·5) | 21·2 (18·7-24·1) |
| Obesity (BMI ≥ 30) – no. (%) | 6,729 (4·3) | 1,241 (3·6) | 5,488 (4·4) |
| Comorbidities – no. (%) | |||
| Malignancy | 1,284 (0·8) | 188 (0·5) | 1,096 (0·9) |
| Immunocompromised | 291 (0·2) | 44 (0·1) | 247 (0·2) |
| Chronic respiratory diseases | 5,652 (3·6) | 1,186 (3·5) | 4,466 (3·6) |
| Chronic kidney diseases | 88 (0·1) | 15 (0·1) | 73 (0·0) |
| Cardiovascular diseases | 1,620 (1·0) | 229 (0·7) | 1,391 (1·1) |
| Cerebrovascular diseases | 102 (0·1) | 22 (0·1) | 80 (0·1) |
| Hypertension | 8,781 (5·6) | 1,270 (3·7) | 7,511 (6·1) |
| Diabetes | 3,740 (2·4) | 550 (1·6) | 3,190 (2·6) |
| SARS-CoV-2 vaccination – no. (%) | |||
| Unvaccinated | 60,033 (38·0) | 15,339 (44·7) | 44,694 (36·2) |
| One dose | 1,052 (0·7) | 341 (1·0) | 711 (0·6) |
| Two doses | 38,304 (24·3) | 11,232 (32·7) | 27,072 (21·9) |
| Three doses | 53,389 (33·8) | 7,424 (21·6) | 45,965 (37·2) |
| Four doses | 5,083 (3·2) | 0 (0·0) | 5,083 (4·1) |
| Previous SARS-CoV-2 infection – no. (%) | 5,767 (3·7) | 732 (2·1) | 5,035 (4·1) |
| Progression to severe disease – no. (%) | 142 (0·1) | 19 (0·1) | 123 (0·1) |
| Among the elderly (Age ≥ 65 years) | 110 (1·01) | 12 (0·83) | 98 (1·04) |
| Among individuals aged < 65 years | 31 (0·02) | 7 (0·02) | 24 (0·02) |
| Death within 30 days – no. | 4 | 2 | 2 |
*
N=157,552
**
N=157,749
***
N=157,781.
BMI, body mass index; IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.